IL6 and colitis: In a DSS-induced murine colitis model, liraglutide treatment significantly reduced histological inflammation scores (from 7.4 ± 0.3 to 2.2 ± 0.5, p < 0.001), and suppressed TNF-α and IL-6 expression by over 60% (9).